VU Research Portal
Targetable genetic signatures of immune evasion in lymphoma
Roemer, M.G.M.
2017
document version
Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
Roemer, M. G. M. (2017). Targetable genetic signatures of immune evasion in lymphoma.
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Table of contents
Chapter 1 General Introduction 7
1.1. The Germinal Center 8
1.2. Non-Hodgkin lymphomas - DLBCL and LBCL subtypes 9 1.3. Hodgkin lymphoma 13
1.4. Role of the immune system in lymphoid malignancies 15
1.5. Immune checkpoint blockade in lymphoid malignancies 19
1.6. Outline and aims of this thesis 20
Chapter 2 Targetable genetic features of primary testicular and primary central nervous system lymphomas 25
Chapter 3 Recurrent genetic alterations of CD274 (PD-L1) and PDCD1GL2 (PD-L2) in T-cell/histiocyte rich large B-cell lymphoma 49
Chapter 4 B-cell and classical Hodgkin lymphomas associated with immunodeficiency 57
Chapter 5 PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome 75
Chapter 6 Chromosome 9p24.1/PD-L1/PD-L2 alterations and PD-L1 expression and treatment outcomes in patients with classical Hodgkin lymphoma treated with Nivolumab (PD-1 blockade) 91
Chapter 7 Classical Hodgkin lymphoma with reduced β2M/MHC class I expression is associated with inferior outcome independent of 9p24.1 status 101
Chapter 8 Discussion 115
8.1. Targetable genetic features of LBCLs 116
8.2. Chromosome 9p24.1 alterations in lymphoid malignancies 120 8.3. Immune evasion in Hodgkin lymphoma 125
8.4. Conclusions 130 Chapter 9 Appendices 135 9.1. Summary 136 9.2. Nederlandse samenvatting 141 9.3. Acknowledgements 148 9.4. List of publications 155
9.5. About the author 157